A Comparison of the Predictors of Abnormal Cervical Cytology among HIV-Positive and HIV-Negative Women Attending Lagos University Teaching Hospital, Nigeria
Main Article Content
Abstract
Background: Women living with Human Immunodeficiency Virus (HIV) are at increased risk of developing premalignant cervical lesions compared with the general population. This study assessed and compared the prevalence and predictors of abnormal cervical cytology among HIV-positive and HIV-negative women attending Lagos University Teaching Hospital, Nigeria.
Methods: A comparative cross-sectional study was conducted among asymptomatic HIV-positive women attending the AIDS Prevention Initiative in Nigeria Clinic and HIV-negative women attending the General Out-Patient Department Clinic. Cervical cytology samples from 441 participants (232 HIV-positive and 209 HIV-negative), selected using systematic random sampling, were evaluated using the Bethesda Classification System. Data were collected using interviewer-administered questionnaires and analyzed with SPSS version 26. Associations were assessed using chi-square tests and multivariable logistic regression at a 5% significance level.
Results: The prevalence of abnormal cervical cytology was significantly higher among HIV-positive women (27.6%) compared to HIV-negative women (5.7%) (p<0.001). A significant difference was observed in the mean ages at sexual initiation among these two groups of women with abnormal cytology. HIV-negative status (adjusted Odds Ratio [aOR]=0.15; 95% Confidence Interval [CI]: 0.07–0.30; p<0.001) and age 30–39 years (aOR=0.38; 95% CI: 0.16–0.92; p=0.032) were associated with lower odds of abnormal cytology, while high parity (≥3) increased the odds (aOR=2.54; 95% CI: 1.41–4.58; p=0.002).
Conclusion: Abnormal cervical cytology was significantly more prevalent among women living with HIV. HIV status, age, and parity were key predictors. Strengthened and targeted cervical cancer screening strategies are recommended for HIV-positive women to facilitate early detection and timely intervention.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi:10.1002/ijc.33588 PubMed PMID: 33818764.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424. doi:10.3322/caac.21492 PubMed PMID: 30207593.
3. Bruni L, Albero G, Serrano B, Mena M, Collado J, Gomez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report [Internet]. 2023 Mar. Report. Available from: www.hpvcentre.net
4. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020 Feb;8(2):e191–203. doi:10.1016/S2214-109X(19)30482-6 PubMed PMID: 31812369.
5. Liu G, Sharma M, Tan N, Barnabas R V. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018 Mar 27;32(6):795–808. doi:10.1097/QAD.0000000000001765 PubMed PMID: 29369827.
6. Debeaudrap P, Sobngwi J, Tebeu PM, Clifford GM. Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virus-infected Women: A Systematic Review and Meta-analysis of Treatment Failure. Clin Infect Dis. 2019 Oct 15;69(9):1555–65. doi:10.1093/cid/ciy1123 PubMed PMID: 30602038.
7. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, et al. HIV Infection and Survival Among Women With Cervical Cancer. J Clin Oncol. 2016 Nov 1;34(31):3749–57. doi:10.1200/JCO.2016.67.9613 PubMed PMID: 27573661.
8. Clifford GM, Gonçalves MAG, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006 Nov 28;20(18):2337–44. doi:10.1097/01.aids.0000253361.63578.14 PubMed PMID: 17117020.
9. UNAIDS. Global HIV statistics: UNAIDS Fact Sheet 2025. 2025. Report.
10. UNAIDS. Country progress report - Nigeria. Global AIDS monitoring. 2020. Report.
11. Avdulla CS, Tachirai N. George N. Papanicolaou (1883-1962): The Pioneer of Cytology and Early Cancer Detection. Cureus. 2024 Sep;16(9):e68999. doi:10.7759/cureus.68999 PubMed PMID: 39385916.
12. Dasgupta S. The Efficiency of Cervical Pap and Comparison of Conventional Pap Smear and Liquid-Based Cytology: A Review. Cureus. 2023 Nov;15(11):e48343. doi:10.7759/cureus.48343 PubMed PMID: 38060751.
13. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
14. National Population Commission (NPC). Population Projection for Nigeria. 2017.
15. Lagos Bureau of Statistics. Abstract of Local Government statistics. 2022.
16. World Bank. Urbanization and Development: Emerging Futures. 2016.
17. National Agency for the Control of AIDS (NACA). Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) Report. 2021.
18. LUTH. Lagos University Teaching Hospital [Internet]. 2022 [cited 2022 Aug 27]. Available from: https://luth.gov.ng/
19. Lagos University Teaching Hospital (LUTH). Annual Report. 2022.
20. Kelsey J, Whitte A, Evans A T. Methods in observational epidemiology. 2nd ed. Oxford Univ Press; 1996.
21. Joseph OU, Charlotte OO, Bertrand NO. Sociodemographic determinants of abnormal cervical cytology among HIV positive women in Nnewi, Nigeria. International Journal of Medicine and Medical Sciences. 2017 Oct 31;9(10):119–25. doi:10.5897/ijmms2017.1322
22. Denslow S, Rositch A, Firnhaber C, Ting J, Smith J. Incidence and progression of cervical lesions in women with HIV: A systematic global review. Int J STD AIDS. 2014;25(3):163–77. doi:10.1177/0956462413491735,
23. de Lemos P, García-Zapata M, Tavares S. Cervical Cytopathology in a Population of HIV-Positive and HIV-Negative Women. J Trop Med. 2012;2012:869758. doi:10.1155/2012/869758
24. Ntuli S, Maimela E, Skaal L, Mogale M, Lekota P. Abnormal cervical cytology amongst women infected with human immunodeficiency virus in Limpopo province, South Africa. Afr J Prim Health Care Fam Med. 2020;12(1):e1–4. doi:10.4102/phcfm.v12i1.2215
25. Jolly P, Mthethwa-Hleta S, Padilla L, Pettis J, Winston S, Akinyemiju T, et al. Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV negative women in Swaziland. BMC Public Health. 2017;17(1):218. doi:10.1186/s12889-017-4120-3
26. Choudhury A, Acharyya T. A study on cervical cytopathology in HIV positive pregnant women in Southern part of Assam, India. Int J Reprod Contracept Obstet Gynecol. 2021;10:3490–3.
27. Choudhury S, Berthaud V, Ladson G, Osijo A. Follow-up of Papanicolaou (Pap) in HIV-positive and HIV-negative Women. Ann Clin Cytol Pathol. 2020;6(2):1137.
28. Gupta R, Hussain S, Hariprasad R, Dhanasekaran K, Verma S, Agarwal V, et al. High Prealence of Cervical High-Grade Lesions and High-Risk Human Papillomairus Infections in Women Living with HIV: A Case for Prioritizing Cervical Screening in this Vulnerable Group. Acta Cytol. 2022;27:1–11.
29. Malik S, Kumari S, Gaikwad H, Mishra A, Bhardwaj M. Prealence of abnormal cervical cytology and HPV DNA positivity among HIV positive women. Int J Reprod Contracept Obstet Gynecol. 2019;8(9):3649.
30. Ogunsowo K, Akadri A, Odelola O, Adefuye P, Shorunmu T, Ebili H. Prevalence and predictors of squamous intraepithelial lesions in human immunodeficiency virus positive women in Sagamu, southwest Nigeria. J Public Health Afr. 2022 Sep 7;13(3). doi:10.4081/jphia.2022.1858
31. Lawal I, Agida T, Offiong R, Oluwole P. Cervical Cytology among HIV Positive and HIV Negative Women in a Tertiary Hospital in North Central Nigeria: A Comparative Study. Ann Med Health Sci Res. 2017;7:308–11.
32. Nwankwo P, Sekoni O, Omokhodion F. Sexual practices and willingness to use female condom among female unergraduate students of the University of Port Harcourt, Rivers State, Nigeria. Afr J Med Med Sci. 2018;47:365–72.
33. Bassey G, Jeremiah I, Ikimalo JI, Fiebai PO, Athanasius BP. Abnormal cervical cytology among HIV-positive women in Nigeria. Int J Gynaecol Obstet. 2014 May;125(2):103–6. doi:10.1016/j.ijgo.2013.10.024 PubMed PMID: 24568957.
34. Faduyile F, Taiwo O, Banjo1 AAF, Abdulkareem F, Akinde1 O, Wright K. The influence of HIV infection on the prevalence and pattern of cervical cytological abnormalities in women in Lagos, Nigeria. Annals of Tropical Pathology. 2012;3(1):31–41.
35. Mekonnen AG, Mittiku YM. Early-onset of sexual activity as a potential risk of cervical cancer in Africa: A review of literature. PLOS global public health. 2023;3(3):e0000941. doi:10.1371/journal.pgph.0000941 PubMed PMID: 36962975.
36. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007 Sep 8;370(9590):890–907. doi:10.1016/S0140-6736(07)61416-0 PubMed PMID: 17826171.
37. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609–21. doi:10.1016/S0140-6736(07)61684-5 PubMed PMID: 17993361.
38. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008 Aug 19;26 Suppl 10:K1-16. doi:10.1016/j.vaccine.2008.05.064 PubMed PMID: 18847553.
39. Louie KS, de Sanjose S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009 Apr 7;100(7):1191–7. doi:10.1038/sj.bjc.6604974 PubMed PMID: 19277042.
40. Ghebre RG, Grover S, Xu MJ, Chuang LT, Simonds H. Cervical cancer control in HIV-infected women: Past, present and future. Gynecol Oncol Rep. 2017 Aug;21:101–8. doi:10.1016/j.gore.2017.07.009 PubMed PMID: 28819634.